1例冠状动脉栓塞伴心房颤动患者的药学监护  

Pharmaceutical Care of a Patient with Coronary Embolism Complicated with Atrial Fibrillation

作　　者：杨莉 江金成 张杰 张先平[1] YANG Li;JIANG Jincheng;ZHANG Jie;ZHANG Xianping(The First People's Hospital of Jingzhou,Jingzhou,Hubei,China 434000)

机构地区：[1]湖北省荆州市第一人民医院,湖北荆州434000

出　　处：《中国药业》2025年第9期123-125,共3页China Pharmaceuticals

摘　　要：目的探讨临床药师在冠状动脉栓塞(CE)伴心房颤动(AF)患者抗栓治疗中发挥的药学监护作用。方法临床药师通过参与1例CE伴AF患者的抗栓治疗过程,查阅文献及分析病例后,协助医师制订急性期及稳定期的抗栓治疗方案,并进行药学监护。结果CE急性期予三联抗栓治疗,病情稳定后予达比加群酯抗凝治疗,预防栓塞事件,未发生出血情况。结论临床药师参与CE伴AF患者的抗栓治疗,可提高其用药依从性,有助于预防血栓栓塞,减少严重出血事件的发生。Objective To investigate the pharmaceutical monitoring role of clinical pharmacists in antithrombotic therapy for patients with coronary embolism(CE)and atrial fibrillation(AF).Methods The clinical pharmacist participated in the antithrombotic treatment process of a patient with CE and AF,reviewed literature and analyzed the patient,assisted the physician in formulating acute and stable antithrombotic treatment plans,and provided pharmaceutical care.Results The patients were given triple antithrombotic therapy in the acute stage of CE and dabigatran etexilate anticoagulant therapy in the stable condition to prevent embolization events,and no bleeding occurred.Conclusion Clinical pharmacists participating in antithrombotic therapy for CE patients with AF can improve their medication compliance,help prevent thromboembolism,and reduce the occurrence of severe bleeding events.

关 键 词：冠状动脉栓塞 心房颤动 抗栓治疗 药学监护 

分 类 号：R95[医药卫生—药学] R972